TAMPA, Fla.--(BUSINESS WIRE)--March 30, 2006--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) (“Nanobac” or “the Company”) announced today new initiatives focusing on diagnostic and therapeutic solutions for stone forming diseases. Capitalizing on its intellectual property estate, recent discoveries and pending intellectual property, the Company will utilize a team of internationally recognized medical and drug development experts to test a promising drug combination and diagnostics that might improve patient outcomes in painful stone-forming diseases such as prostatitis, gallstones and kidney stones where no effective treatment is available.
